Ключевые слова
Аннотация
Tugunchali periarteriit o‘rta kalibrli arteriyalarni zararlovchi kam uchraydigan tizimli nekrotik vaskulit bo‘lib, ko‘pincha buyraklarni ham zararlaydi. Buyrak ishtiroki kasallikning og‘ir kechishi va bemor prognoziga sezilarli ta’sir ko‘rsatadi, ishemik shikastlanish, arterial gipertenziya, proteinuriya va surunkali buyrak yetishmovchiligiga olib kelishi mumkin. An’anaviy immunosupressiv terapiya, jumladan glyukokortikosteroidlar va sitotoksik preparatlar yallig‘lanishni nazorat qilishda asosiy vosita hisoblanadi. Shu bilan birga, biologik va maqsadli immunoterapiya yangi zamonaviy yondashuv sifatida samarali va nojo‘ya ta’sirlarni kamaytiruvchi davolash strategiyalarini taqdim etadi. Erta tashxis, individualizatsiyalangan terapiya va multidisiplinar yondashuv buyrak funksiyasini saqlash, kasallik faolligini kamaytirish va bemor hayot sifatini yaxshilashda muhim ahamiyatga ega.
Библиографические ссылки
Pagnoux, C. (2016). Polyarteritis nodosa. Orphanet Journal of Rare Diseases, 11(1), 1–15.
Jennette, J. C., Falk, R. J., Bacon, P. A., Basu, N., Cid, M. C., Ferrario, F., et al. (2013). 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis & Rheumatism, 65(1), 1–11.
Stone, J. H., & Hellmann, D. B. (2010). Vasculitis: diagnosis and management. The Lancet, 376(9754), 1603–1616.
Merkel, P. A., & Seo, P. (2019). Vasculitis-associated renal disease. Clinical Journal of the American Society of Nephrology, 14(9), 1404–1412.
Watts, R. A., & Robson, J. (2018). Introduction, epidemiology and classification of vasculitis. Best Practice & Research Clinical Rheumatology, 32(1), 3–20.